INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY) announced today that Anat Ashkenazi has resigned from her position as Chief Financial Officer (CFO) to explore a new career... ByInvesting.com ...

Ashkenazi began her tenure as CFO on July 31, joining the tech giant from an impressive career as finance chief at drugmaker Eli Lilly. On her debut earnings call in Q3 last October, she stated ...

One of the highlights of Eli Lilly's third-quarter results ... said Lilly's chief financial officer Anat Ashkenazi on the call. Now, Lilly's focus is on international expansion – with approvals ...

We disagree as this is an AI Arms Race and Alphabet is making the right moves at the right time. While this quarter was not a home run, we believe the stock down this much is an overreaction and we ...

The new CFO, Anat Ashkenazi, you might remember, she was at Eli Lilly, she tells a terrific story. We’ll be listening for anything about the growth of Google’s cloud infrastructure business.

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

For years, Eli Lilly has been generating solid growth numbers -- but lately, they've been accelerating rapidly. The company is coming off a solid quarter where its revenue rose by 45% for the last ...

Eli Lilly expands its partnership with AdvanCell to advance targeted alpha therapies using Pb-212 technology for cancer treatment. Lilly inks a global licensing deal with OliX for OLX75016 ...

Copyright 2025 The Associated Press. All Rights Reserved. A sign for Eli Lilly & Co. appears outside their corporate headquarters in Indianapolis on April 26, 2017 ...

On Monday, Eli Lilly And Co (NYSE:LLY) inked two strategic collaborations to expand radiopharmaceuticals and metabolic-associated steatohepatitis (MASH), respectively. AdvanCell announced that it ...